Gilead Sciences (GILD) 88.86 $GILD
Final Glance: Biotechnology companies
AP - Mon Jul 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Gilead Earnings: Can Sovaldi Reach $3 Billion?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 21, 4:00PM CDT
Gilead Sciences reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi...
Biogen Shares Rebound As Street Has A Change Of Heart
at Investor's Business Daily - Mon Jul 21, 3:09PM CDT
Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. The No. 3 biotech by market...
Why I'm Shorting Gilead: Sentiment Is Too Positive Ahead of Earnings
at The Street - Mon Jul 21, 2:04PM CDT
Nobody thinks it's possible Gilead can sell off, bit it can. I dispel the hype and go short.
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Midday Glance: Biotechnology companies
AP - Mon Jul 21, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Mon Jul 21, 10:38AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding?
at The Street - Mon Jul 21, 7:22AM CDT
Shares of Gilead Sciences (GILD) are up in pre-market trade as the company's Solvadi drug helps cure hepatitis C in people with HIV, according to researchers.
Are Insurers Playing Fair With HIV Patients?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 20, 1:00PM CDT
A new complaint claims that insurers may be flouting a key provision of the Affordable Care Act that prevents discrimination. As part of health-care insurance reform, this provision prevents insurers from denying coverage or pricing their plans based...
Roundtable: 3 Stocks Preparing to Shock the Market
Motley Fool Staff - Motley Fool - Sat Jul 19, 4:16PM CDT
Earnings season is upon us, so we decided to ask our top health care contributors to identify the stock they're watching to surprise on earnings. Here are the companies they singled out. George Budwell : Next week, I expect Cubist...
India Just Did What Millions of Americans Wish the U.S. Government Would Do
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 9:32AM CDT
The United States is unquestionably the premier economic superpower around the globe. It has the highest GDP, the greatest number of world-renowned universities, and of course has the most followed financial markets around the globe. Compared to...
Facebook, Gilead Headline IBD 50's Top 5 Earnings
at Investor's Business Daily - Sat Jul 19, 7:02AM CDT
With earnings season in full force, investors should focus on the very best companies. The elite IBD 50 ranks top-rated growth stocks, factoring in strong relative price strength and top fundamentals. The IBD 50 has several companies reporting...
Gilead Sciences Stock's Huge Hidden Opportunity
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jul 18, 4:00PM CDT
If you haven't heard about Gilead 's Sovaldi, the hepatitis c cure, you haven't been paying attention. The whole market is aware of the $2.3 billion wonder drug and the fight over its cost. But Sovaldi isn't Gilead's only wonder drug. There is...
Stocks Up In Late Trade; AerCap Nears Resistance
at Investor's Business Daily - Fri Jul 18, 1:57PM CDT
Stocks continued to add to broad gains in late trading Friday and were on pace to end modestly higher on the week. The Nasdaq stretched its gain to 1.5%. It has erased all of Thursday's loss and then some. Meanwhile, the S&P 50 rallied 1%, and the...
Stocks Add To Gains; Under Armour Rebounds
at Investor's Business Daily - Fri Jul 18, 10:53AM CDT
Stocks pushed ahead and were at session highs near Friday's midpoint. Helped by chip, solar and Internet stocks, the Nasdaq outperformed with a 1% gain. The S&P 500 climbed 0.7%. Both major indexes have regained more than half of Thursday's losses....
Uptrend Call Working As Gilead Sciences Stock Rises 17.2% (GILD)
Comtex SmarTrend(R) - Thu Jul 17, 5:28PM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 17.25% as of today's recent price of $85.07.
After Yesterday's Decline of 2.22%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 17, 4:08PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.75 to a high of $88.17. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $85.82 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Gilead Sciences Falls 2.22% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 17, 4:07PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.75 to a high of $88.17. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $85.82 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Final Glance: Biotechnology companies
AP - Mon Jul 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Gilead Earnings: Can Sovaldi Reach $3 Billion?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 21, 4:00PM CDT
Gilead Sciences reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi...
Biogen Shares Rebound As Street Has A Change Of Heart
at Investor's Business Daily - Mon Jul 21, 3:09PM CDT
Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. The No. 3 biotech by market...
Why I'm Shorting Gilead: Sentiment Is Too Positive Ahead of Earnings
at The Street - Mon Jul 21, 2:04PM CDT
Nobody thinks it's possible Gilead can sell off, bit it can. I dispel the hype and go short.
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Midday Glance: Biotechnology companies
AP - Mon Jul 21, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Mon Jul 21, 10:38AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding?
at The Street - Mon Jul 21, 7:22AM CDT
Shares of Gilead Sciences (GILD) are up in pre-market trade as the company's Solvadi drug helps cure hepatitis C in people with HIV, according to researchers.
Are Insurers Playing Fair With HIV Patients?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 20, 1:00PM CDT
A new complaint claims that insurers may be flouting a key provision of the Affordable Care Act that prevents discrimination. As part of health-care insurance reform, this provision prevents insurers from denying coverage or pricing their plans based...
Roundtable: 3 Stocks Preparing to Shock the Market
Motley Fool Staff - Motley Fool - Sat Jul 19, 4:16PM CDT
Earnings season is upon us, so we decided to ask our top health care contributors to identify the stock they're watching to surprise on earnings. Here are the companies they singled out. George Budwell : Next week, I expect Cubist...
India Just Did What Millions of Americans Wish the U.S. Government Would Do
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 9:32AM CDT
The United States is unquestionably the premier economic superpower around the globe. It has the highest GDP, the greatest number of world-renowned universities, and of course has the most followed financial markets around the globe. Compared to...
Facebook, Gilead Headline IBD 50's Top 5 Earnings
at Investor's Business Daily - Sat Jul 19, 7:02AM CDT
With earnings season in full force, investors should focus on the very best companies. The elite IBD 50 ranks top-rated growth stocks, factoring in strong relative price strength and top fundamentals. The IBD 50 has several companies reporting...
Gilead Sciences Stock's Huge Hidden Opportunity
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jul 18, 4:00PM CDT
If you haven't heard about Gilead 's Sovaldi, the hepatitis c cure, you haven't been paying attention. The whole market is aware of the $2.3 billion wonder drug and the fight over its cost. But Sovaldi isn't Gilead's only wonder drug. There is...
Stocks Up In Late Trade; AerCap Nears Resistance
at Investor's Business Daily - Fri Jul 18, 1:57PM CDT
Stocks continued to add to broad gains in late trading Friday and were on pace to end modestly higher on the week. The Nasdaq stretched its gain to 1.5%. It has erased all of Thursday's loss and then some. Meanwhile, the S&P 50 rallied 1%, and the...
Stocks Add To Gains; Under Armour Rebounds
at Investor's Business Daily - Fri Jul 18, 10:53AM CDT
Stocks pushed ahead and were at session highs near Friday's midpoint. Helped by chip, solar and Internet stocks, the Nasdaq outperformed with a 1% gain. The S&P 500 climbed 0.7%. Both major indexes have regained more than half of Thursday's losses....
Uptrend Call Working As Gilead Sciences Stock Rises 17.2% (GILD)
Comtex SmarTrend(R) - Thu Jul 17, 5:28PM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 17.25% as of today's recent price of $85.07.
After Yesterday's Decline of 2.22%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 17, 4:08PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.75 to a high of $88.17. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $85.82 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Gilead Sciences Falls 2.22% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 17, 4:07PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $84.75 to a high of $88.17. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $85.82 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
